First Pharma

Consumer Health Company

Background

First Pharma, aa profitable, growing and scalable Australian Consumer Health
company, selected Plexus Ventures to manage the sale of the business to allow the
founders and investors to exit. The company offered a portfolio of owned and licensed
brands in various categories: skin care, antifungal, topical pain and scar segments.

Objective

Divestment of the Company to a strategic seeking to acquire 100% of the business to
scale the established CHC platform.

Process

Plexus Ventures prepared a comprehensive suite of non-confidential and confidential
materials to support the divestment process. In September 2023, Plexus approached 60
companies with a strategic interest in the Australian market to drive competitive tension
around the asset package. Multiple non-binding offers were received, with selected
parties progressing to due diligence. Following this phase, a shortlist of parties entered
into negotiations for a definitive agreement.

Outcome

In December 2023, in less than a 4 month search, Plexus succeeded in arranging
execution of a deal between the First Pharma and an emerging Australian pharma and CHC company, owned by a well-known German entrepreneur.